Cohn Robbins Holdings Corp. is a blank check company founded for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company intends to capitalize on the approximately 70 years of combined experience of its founders in investing and managing capital across markets and industries, structuring transactions, and building businesses. While the company may pursue an acquisition in any business industry or sector, there are attractive trends in several industries where its founders have particular expertise, including consumer and, within the technology sector, software and fintech. The company intends to target large, private equity and venture capital-owned assets, founder-led businesses and corporate carve-outs.
Zovio is an education technology services company that partners with higher education institutions and employers to deliver innovative, personalized solutions to help learners and leaders achieve their aspirations. The Zovio network, which includes Fullstack Academy, TutorMe, and Learn@Forbes, leverages its core strengths and applies its technology and capabilities to priority market needs. Using advanced data and analytics, Zovio identifies the most meaningful ways to enhance the learner experience and deliver strong outcomes for higher education institutions, employers, and learners. Zovio's purpose is to help everyone be in a class of their own.
(US) Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK). Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need. Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035. In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).
you spend 40-60% of your time on the road. your office is wherever you are, not where your broker is. real is a brokerage that works the way you do. real provides the technology to run your operation from your smartphone, a split of 85/15% with commission cap (allowing you to achieve 100%) and an on-demand support team to help you along the way. with us, there’s no mandatory meetings, no long morning commutes – just you & your ambition. marketing collateral, instant cmas, personal idx-integrated website, client crm & more – all at your fingertips, all in one app. lastly, kiss those huge office / transaction / franchise fees goodbye. you’ve felt it – real estate is changing. the typical brokerage model that has existed for years is beginning to crack. real is on the forefront of redefining this industry, and we want salespeople, realtors, real estate agents & brokers like you to come along for the ride.
(US) XL Fleet is a leading provider of vehicle electrification solutions for commercial and municipal fleets in North America, with more than 145 million miles driven by customers such as The Coca-Cola Company, Verizon, Yale University and the City of Boston. XL Fleet’s hybrid and plug-in hybrid electric drive systems can increase fuel economy up to 25-50 percent and reduce carbon dioxide emissions up to 20-33 percent, decreasing operating costs and meeting sustainability goals while enhancing fleet operations. XL Fleet’s plug-in hybrid electric drive system was named one of TIME magazine's best inventions of 2019.